Enterprise Financial Services Corp Bristol Myers Squibb CO Transaction History

Enterprise Financial Services Corp

$177 Million
Q4 2024

A detailed history of Enterprise Financial Services Corp transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Enterprise Financial Services Corp holds 8,396 shares of BMY stock, worth $512,911. This represents 0.27% of its overall portfolio holdings.

Number of Shares

8,396

Previous 8,476 0.94%

Holding current value

$512,911

Previous $438,000 8.22%

% of portfolio

0.27%

Previous 0.26%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 07, 2025	SELL	$51.92 - $59.94 $4,153 - $4,795	-80 Reduced 0.94%	8,396 $474,000
Q3 2024 Nov 12, 2024	SELL	$39.66 - $51.75 $30,736 - $40,106	-775 Reduced 8.38%	8,476 $438,000
Q2 2024 Aug 13, 2024	SELL	$40.25 - $52.99 $20,245 - $26,653	-503 Reduced 5.16%	9,251 $384,000
Q1 2024 May 14, 2024	SELL	$47.98 - $54.4 $50,618 - $57,392	-1,055 Reduced 9.76%	9,754 $528,000
Q4 2023 Feb 09, 2024	SELL	$48.48 - $57.85 $115,867 - $138,261	-2,390 Reduced 18.11%	10,809 $554,000
Q3 2023 Oct 31, 2023	SELL	$57.89 - $64.73 $46,543 - $52,042	-804 Reduced 5.74%	13,199 $766,000
Q2 2023 Aug 11, 2023	BUY	$63.71 - $70.74 $16,437 - $18,250	258 Added 1.88%	14,003 $895,000
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $18,398 - $20,868	-280 Reduced 2.0%	13,745 $952,000
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $4,793 - $5,676	70 Added 0.5%	14,025 $1.01 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $45 - $27,124	-353 Reduced 2.47%	13,955 $992,000
Q2 2022 Aug 09, 2022	BUY	$72.62 - $79.98 $24,690 - $27,193	340 Added 2.43%	14,308 $1.1 Million
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $15,800 - $18,946	257 Added 1.87%	13,968 $1.02 Million
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $1.01 Million - $1.17 Million	-18,763 Reduced 57.78%	13,711 $855,000
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $1.02 Million - $1.19 Million	17,222 Added 112.92%	32,474 $1.92 Million
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $27,488 - $29,934	-444 Reduced 2.83%	15,252 $1.02 Million
Q1 2021 May 13, 2021	SELL	$59.34 - $66.74 $11,630 - $13,081	-196 Reduced 1.23%	15,696 $990,000
Q4 2020 Feb 12, 2021	SELL	$57.74 - $65.43 $63,860 - $72,365	-1,106 Reduced 6.51%	15,892 $986,000
Q3 2020 Nov 13, 2020	SELL	$57.43 - $63.64 $38,248 - $42,384	-666 Reduced 3.77%	16,998 $1.03 Million
Q2 2020 Aug 04, 2020	SELL	$54.82 - $64.09 $338,239 - $395,435	-6,170 Reduced 25.89%	17,664 $1.04 Million
Q1 2020 May 15, 2020	BUY	$46.4 - $67.43 $33,779 - $49,089	728 Added 3.15%	23,834 $1.33 Million
Q4 2019 Jan 28, 2020	SELL	$49.21 - $64.19 $22,292 - $29,078	-453 Reduced 1.92%	23,106 $1.48 Million
Q3 2019 Oct 31, 2019	SELL	$42.77 - $50.71 $121,167 - $143,661	-2,833 Reduced 10.73%	23,559 $1.19 Million
Q2 2019 Jul 30, 2019	SELL	$44.62 - $49.34 $165,049 - $182,508	-3,699 Reduced 12.29%	26,392 $1.2 Million
Q1 2019 Apr 26, 2019	BUY	$45.12 - $53.8 $627,122 - $747,766	13,899 Added 85.84%	30,091 $1.44 Million
Q4 2018 Jan 25, 2019	SELL	$48.76 - $63.23 $20,381 - $26,430	-418 Reduced 2.52%	16,192 $842,000
Q3 2018 Oct 26, 2018	SELL	$55.19 - $62.25 $14,625 - $16,496	-265 Reduced 1.57%	16,610 $1.03 Million
Q2 2018 Jul 27, 2018	SELL	$50.53 - $62.98 $20,212 - $25,192	-400 Reduced 2.32%	16,875 $934,000
Q1 2018 Apr 27, 2018	BUY	$59.92 - $68.98 $338,548 - $389,737	5,650 Added 48.6%	17,275 $1.09 Million
Q4 2017 Jan 26, 2018	BUY	$59.94 - $65.35 $59,520 - $64,892	993 Added 9.34%	11,625 $713,000
Q3 2017 Oct 27, 2017	BUY	$55.23 - $63.74 $587,205 - $677,683	10,632	10,632 $678,000

Others Institutions Holding BMY

# of Institutions

2,761

Shares Held

1.57B

Call Options Held

28M

Put Options Held

28.7M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $130B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Enterprise Financial Services Corp, based on Form 13F filings with the SEC.

News

Stay updated on Enterprise Financial Services Corp with notifications on news.

Account

Enterprise Financial Services Corp Bristol Myers Squibb CO Transaction History